bpc 157 illegal in australia BPC-157 | Batch-Tested Research Reference Therapeutic Goods Administration issues safety

Yes, when administered by a trained provider using pharmaceutical-grade compounds

Users in different climates face distinct obstacles to peptide preservation

Adverse Reactions/Side Effects The following serious adverse reactions are described below or elsewhere in the prescribing information: Risk of Thyroid C-cell Tumors [see Warnings and Precautions (5.1)] Acute Pancreatitis [see Warnings and Precautions (5.2)] Hypoglycemia with Concomitant Use of Insulin Secretagogues or Insulin [see Warnings and Precautions (5.3)] Hypersensitivity Reactions [see Warnings and Precautions (5.4)] Acute Kidney Injury Due to Volume Depletion [see Warnings and Precautions (5.5)] Severe Gastrointestinal Adverse Reactions [see Warnings and Precautions (5.6)] Diabetic Retinopathy Complications in Patients with a History of Diabetic Retinopathy [see Warnings and Precautions (5.7)] Acute Gallbladder Disease [see Warnings and Precautions (5.8)] Pulmonary Aspiration During General Anesthesia or Deep Sedation [see Warnings and Precautions (5.9)] 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice

2023;238(3):e14001

The metabolic benefits of MOTS-c are cumulative over weeks, not dependent on perfect adherence to every single dose

Emerging use of BPC-157 in orthopaedic sports medicine: a systematic review (2025)